Intratumoral Restoration of miR-137 Plus Cholesterol Favors Homeostasis of the miR-137/Coactivator p160/AR Axis and Negatively Modulates Tumor Progression in Advanced Prostate Cancer

Imagem de Miniatura
Arquivos
art_PIMENTA_Intratumoral_Restoration_of_miR137_Plus_Cholesterol_Favors_Homeostasis_2023.PDF (14.47 MB)
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
MDPI
Autores
GONCALVES, Guilherme L.
Citação
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, v.24, n.11, article ID 9633, 16p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
MicroRNAs (miRNAs) have gained a prominent role as biomarkers in prostate cancer (PCa). Our study aimed to evaluate the potential suppressive effect of miR-137 in a model of advanced PCa with and without diet-induced hypercholesterolemia. In vitro, PC-3 cells were treated with 50 pmol of mimic miR-137 for 24 h, and gene and protein expression levels of SRC-1, SRC-2, SRC-3, and AR were evaluated by qPCR and immunofluorescence. We also assessed migration rate, invasion, colony-forming ability, and flow cytometry assays (apoptosis and cell cycle) after 24 h of miRNA treatment. For in vivo experiments, 16 male NOD/SCID mice were used to evaluate the effect of restoring miR-137 expression together with cholesterol. The animals were fed a standard (SD) or hypercholesterolemic (HCOL) diet for 21 days. After this, we xenografted PC-3 LUC-MC6 cells into their subcutaneous tissue. Tumor volume and bioluminescence intensity were measured weekly. After the tumors reached 50 mm3, we started intratumor treatments with a miR-137 mimic, at a dose of 6 mu g weekly for four weeks. Ultimately, the animals were killed, and the xenografts were resected and analyzed for gene and protein expression. The animals' serum was collected to evaluate the lipid profile. The in vitro results showed that miR-137 could inhibit the transcription and translation of the p160 family, SRC-1, SRC-2, and SRC-3, and indirectly reduce the expression of AR. After these analyses, it was determined that increased miR-137 inhibits cell migration and invasion and impacts reduced proliferation and increased apoptosis rates. The in vivo results demonstrated that tumor growth was arrested after the intratumoral restoration of miR-137, and proliferation levels were reduced in the SD and HCOL groups. Interestingly, the tumor growth retention response was more significant in the HCOL group. We conclude that miR-137 is a potential therapeutic miRNA that, in association with androgen precursors, can restore and reinstate the AR-mediated axis of transcription and transactivation of androgenic pathway homeostasis. Further studies involving the miR-137/coregulator/AR/cholesterol axis should be conducted to evaluate this miR in a clinical context.
Palavras-chave
prostate cancer, hypercholesterolemic model, p160, microRNA
URI
https://observatorio.fm.usp.br/handle/OPI/54544
Referências
  1. Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005
  2. Balaguer F, 2010, CANCER RES, V70, P6609, DOI 10.1158/0008-5472.CAN-10-0622
  3. Bhattarai A, 2021, STEROIDS, V173, DOI 10.1016/j.steroids.2021.108878
  4. Chandrasekar T, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0457-6
  5. Citron F, 2017, CLIN CANCER RES, V23, P3769, DOI 10.1158/1078-0432.CCR-16-2814
  6. de Camargo JA, 2021, INT J BIOL MARKER, V36, P50, DOI 10.1177/1724600821997461
  7. de Moraes RP, 2021, MOL BIOL RES COMMUN, V10, P149, DOI 10.22099/mbrc.2021.40912.1646
  8. Eedunuri VK, 2015, MOL ENDOCRINOL, V29, P1170, DOI 10.1210/me.2015-1080
  9. Iscaife A, 2018, APOPTOSIS, V23, P388, DOI 10.1007/s10495-018-1461-z
  10. Ivanovic RF, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4930-4
  11. Ivanovic RF, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0516-0
  12. Katz B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113700
  13. Lee YS, 2009, ANNU REV PATHOL-MECH, V4, P199, DOI 10.1146/annurev.pathol.4.110807.092222
  14. Leite KRM, 2015, UROL ONCOL-SEMIN ORI, V33, DOI 10.1016/j.urolonc.2015.03.002
  15. Leite KRM, 2013, UROL ONCOL-SEMIN ORI, V31, P796, DOI 10.1016/j.urolonc.2011.07.002
  16. Leite KRM, 2013, CLINICS, V68, P797, DOI 10.6061/clinics/2013(06)12
  17. Leite KRM, 2011, J UROLOGY, V185, P1118, DOI 10.1016/j.juro.2010.10.035
  18. Leite KRM, 2011, UROL ONCOL-SEMIN ORI, V29, P265, DOI 10.1016/j.urolonc.2009.02.002
  19. Li XY, 2016, ONCOTARGET, V7, P12869, DOI 10.18632/oncotarget.7331
  20. Nilsson EM, 2015, ONCOTARGET, V6, P35710, DOI 10.18632/oncotarget.5958
  21. Pimenta Ruan, 2022, Cell Physiol Biochem, V56, P1, DOI 10.33594/000000592
  22. Pimenta Ruan Ca, 2018, Tumour Biol, V40, p1010428318803011, DOI 10.1177/1010428318803011
  23. Pisano C, 2021, CRIT REV ONCOL HEMAT, V157, DOI 10.1016/j.critrevonc.2020.103185
  24. Rane JK, 2015, EUR UROL, V67, P7, DOI 10.1016/j.eururo.2014.09.005
  25. Reis ST, 2013, CLINICS, V68, P652, DOI 10.6061/clinics/2013(05)12
  26. Reis ST, 2012, BMC UROL, V12, DOI 10.1186/1471-2490-12-14
  27. Shtivelman E, 2014, ONCOTARGET, V5, P7217, DOI 10.18632/oncotarget.2406
  28. Singh G, 2017, INDIAN J MED RES, V146, P38, DOI 10.4103/ijmr.IJMR_1639_15
  29. Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304
  30. Stoykova GE, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112626
  31. Suzuki H, 2012, MOL ONCOL, V6, P567, DOI 10.1016/j.molonc.2012.07.007
  32. Varkaris A, 2014, CANCER METAST REV, V33, P595, DOI 10.1007/s10555-013-9481-1
  33. Vejnar CE, 2012, NUCLEIC ACIDS RES, V40, P11673, DOI 10.1093/nar/gks901
  34. Wong N, 2015, NUCLEIC ACIDS RES, V43, pD146, DOI 10.1093/nar/gku1104
  35. Ylitalo EB, 2017, EUR UROL, V71, P776, DOI 10.1016/j.eururo.2016.07.033
  36. Yoon AJ, 2020, HEAD NECK-J SCI SPEC, V42, P1699, DOI 10.1002/hed.26089

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/13
Artigos e Materiais de Revistas Científicas - LIM/26
Artigos e Materiais de Revistas Científicas - LIM/55
Artigos e Materiais de Revistas Científicas - ODS/03